{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:50:49Z","timestamp":1787017849781,"version":"build-2736575974"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"9","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2009,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Although epidemiologic evidence for the ability of combined oral contraception (OC) to reduce the risk of ovarian cancer (OvCa) is convincing, the biological mechanisms underlying this effect are largely unknown. We conducted the present study to determine if OC also influences ovarian carcinogenesis in a genetic mouse model and, if so, to investigate the mechanism underlying the protective effect. LSL-K-rasG12D\/+PtenloxP\/loxP mice were treated with ethinyl estradiol plus norethindrone, contraceptive hormones commonly used in combined OC, or norethindrone alone, or a gonadotropin-releasing hormone agonist. The combined OC had a 29% reduction in mean total tumor weight compared with placebo (epithelial tumor weight, \u221280%). Norethindrone alone reduced mean total tumor weight by 42% (epithelial tumor weight, \u221246%), and the gonadotropin-releasing hormone agonist increased mean total tumor weight by 71% (epithelial tumor weight, +150%). Large variations in tumor size affected the P values for these changes, which were not statistically significant. Nonetheless, the OC reductions are consistent with the epidemiologic data indicating a protective effect of OC. Matrix metalloproteinase-2 activity was decreased in association with OC, indicating that OC may affect ovarian carcinogenesis by decreasing proteolytic activity, an important early event in the pathogenesis of OvCa. In contrast, OC increased invasion in a K-ras\/Pten OvCa cell line established from the mouse tumors, suggesting that OC hormones, particularly estrogen, may have a detrimental effect after the disease process is under way. Our study results support further investigation of OC effects and mechanisms for OvCa prevention.<\/jats:p>","DOI":"10.1158\/1940-6207.capr-08-0236","type":"journal-article","created":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T22:06:39Z","timestamp":1252447599000},"page":"792-799","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effects of Oral Contraceptives or a Gonadotropin-Releasing Hormone Agonist on Ovarian Carcinogenesis in Genetically Engineered Mice"],"prefix":"10.1158","volume":"2","author":[{"given":"Iris L.","family":"Romero","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Obstetrics and Gynecology-Center for Integrative Science and 2Department of Pathology, University of Chicago, Chicago, Illinois and 3Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilyssa O.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Obstetrics and Gynecology-Center for Integrative Science and 2Department of Pathology, University of Chicago, Chicago, Illinois and 3Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujatha","family":"Jagadeeswaran","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Obstetrics and Gynecology-Center for Integrative Science and 2Department of Pathology, University of Chicago, Chicago, Illinois and 3Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keeley L.","family":"Mui","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Obstetrics and Gynecology-Center for Integrative Science and 2Department of Pathology, University of Chicago, Chicago, Illinois and 3Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Seok","family":"Lee","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Obstetrics and Gynecology-Center for Integrative Science and 2Department of Pathology, University of Chicago, Chicago, Illinois and 3Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela M.","family":"Dinulescu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Obstetrics and Gynecology-Center for Integrative Science and 2Department of Pathology, University of Chicago, Chicago, Illinois and 3Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas N.","family":"Krausz","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Obstetrics and Gynecology-Center for Integrative Science and 2Department of Pathology, University of Chicago, Chicago, Illinois and 3Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen H.","family":"Kim","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Obstetrics and Gynecology-Center for Integrative Science and 2Department of Pathology, University of Chicago, Chicago, Illinois and 3Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Gilliam","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Obstetrics and Gynecology-Center for Integrative Science and 2Department of Pathology, University of Chicago, Chicago, Illinois and 3Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Lengyel","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Obstetrics and Gynecology-Center for Integrative Science and 2Department of Pathology, University of Chicago, Chicago, Illinois and 3Brigham Women's Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2009,9,10]]},"reference":[{"key":"2022060815534698600_bib1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","article-title":"Cancer statistics, 2007","volume":"57","author":"Jemal","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"2022060815534698600_bib2","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ajog.2005.05.005","article-title":"Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial","volume":"193","author":"Buys","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"2022060815534698600_bib3","doi-asserted-by":"crossref","first-page":"i","DOI":"10.3310\/hta2020","article-title":"Screening for ovarian cancer: a systematic review","volume":"2","author":"Bell","year":"1998","journal-title":"Health Technol Assess"},{"key":"2022060815534698600_bib4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ijc.10696","article-title":"Long-term effects of oral contraceptives on ovarian cancer risk","volume":"102","author":"Bosetti","year":"2002","journal-title":"Int J Cancer"},{"key":"2022060815534698600_bib5","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/oxfordjournals.aje.a117055","article-title":"A case-control study of oral contraceptive use and invasive epithelial ovarian cancer","volume":"139","author":"Rosenberg","year":"1994","journal-title":"Am J Epidemiol"},{"key":"2022060815534698600_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/EDE.0b013e31816334c5","article-title":"Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects","volume":"19","author":"Lurie","year":"2008","journal-title":"Epidemiology"},{"key":"2022060815534698600_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/aje\/kwm157","article-title":"Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk","volume":"166","author":"Tworoger","year":"2007","journal-title":"Am J Epidemiol"},{"key":"2022060815534698600_bib8","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(08)60167-1","article-title":"Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls","volume":"371","author":"Beral","year":"2008","journal-title":"Lancet"},{"key":"2022060815534698600_bib9","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0140-6736(71)92335-X","article-title":"Incessant ovulation\u2014a factor in ovarian neoplasia?","volume":"2","author":"Fathalla","year":"1971","journal-title":"Lancet"},{"key":"2022060815534698600_bib10","first-page":"717","article-title":"Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis","volume":"71","author":"Cramer","year":"1983","journal-title":"J Natl Cancer Inst"},{"key":"2022060815534698600_bib11","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1002\/(SICI)1097-0142(19970515)79:10<1944::AID-CNCR15>3.0.CO;2-V","article-title":"Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines","volume":"79","author":"Bu","year":"1997","journal-title":"Cancer"},{"key":"2022060815534698600_bib12","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.canlet.2004.09.011","article-title":"Effects of progesterone on ovarian tumorigenesis in xenografted mice","volume":"221","author":"McDonnel","year":"2005","journal-title":"Cancer Lett"},{"key":"2022060815534698600_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/nm1173","article-title":"Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer","volume":"11","author":"Dinulescu","year":"2005","journal-title":"Nat Med"},{"key":"2022060815534698600_bib14","first-page":"1389","article-title":"Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer","volume":"63","author":"Connolly","year":"2003","journal-title":"Cancer Res"},{"key":"2022060815534698600_bib15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ccr.2007.02.016","article-title":"Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt\/\u03b2-catenin and PI3K\/Pten signaling pathways","volume":"11","author":"Wu","year":"2007","journal-title":"Cancer Cell"},{"key":"2022060815534698600_bib16","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1038\/modpathol.3800306","article-title":"Origins and molecular pathology of ovarian cancer","volume":"18 Suppl 2","author":"Bell","year":"2005","journal-title":"Mod Pathol"},{"key":"2022060815534698600_bib17","first-page":"2095","article-title":"Frequent PTEN\/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors","volume":"58","author":"Obata","year":"1998","journal-title":"Cancer Res"},{"key":"2022060815534698600_bib18","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/S0002-9440(10)64681-0","article-title":"Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas","volume":"158","author":"Kurose","year":"2001","journal-title":"Am J Pathol"},{"key":"2022060815534698600_bib19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/aje\/kwg177","article-title":"Reproductive factors and epithelial ovarian cancer risk by histologic type: a multiethnic case-control study","volume":"158","author":"Tung","year":"2003","journal-title":"Am J Epidemiol"},{"key":"2022060815534698600_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/gene.10036","article-title":"Cre\/loxP-mediated inactivation of the murine Pten tumor suppressor gene","volume":"32","author":"Lesche","year":"2002","journal-title":"Genesis"},{"key":"2022060815534698600_bib21","first-page":"2762","article-title":"Human ovarian carcinoma cells maintained on extracellular matrix versus plastic","volume":"43","author":"Crickard","year":"1983","journal-title":"Cancer Res"},{"key":"2022060815534698600_bib22","article-title":"Isolation and propagation of mouse embryonic fibroblasts and preparation of mouse embryonic feeder layer cells","author":"A","year":"2007","journal-title":"Curr Protoc Stem Cell Biol"},{"key":"2022060815534698600_bib23","first-page":"2396","article-title":"Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer","volume":"7","author":"Schmalfeldt","year":"2001","journal-title":"Clin Cancer Res"},{"key":"2022060815534698600_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0076-6879(01)33049-5","article-title":"Ras regulation of urokinase-type plasminogen activator","volume":"333","author":"Lengyel","year":"2001","journal-title":"Methods Enzymol"},{"key":"2022060815534698600_bib25","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/0008-5472.CAN-06-1147","article-title":"c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion","volume":"67","author":"Sawada","year":"2007","journal-title":"Cancer Res"},{"key":"2022060815534698600_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF01463655","article-title":"Methods in quantitative image analysis","volume":"105","author":"Oberholzer","year":"1996","journal-title":"Histochem Cell Biol"},{"key":"2022060815534698600_bib27","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1158\/1078-0432.CCR-05-2338","article-title":"The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer","volume":"12","author":"Kamat","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022060815534698600_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1172\/JCI33775","article-title":"The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin","volume":"118","author":"Kenny","year":"2008","journal-title":"J Clin Invest"},{"key":"2022060815534698600_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/cncr.23956","article-title":"Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin","volume":"115","author":"Pearce","year":"2009","journal-title":"Cancer"},{"key":"2022060815534698600_bib30","first-page":"271","article-title":"Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis?","volume":"5","author":"Rodriguez","year":"1998","journal-title":"J Soc Gynecol Investig"},{"key":"2022060815534698600_bib31","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1006\/gyno.1999.5413","article-title":"Antitumor effect of GnRH agonist in epithelial ovarian cancer","volume":"74","author":"Kim","year":"1999","journal-title":"Gynecol Oncol"},{"key":"2022060815534698600_bib32","doi-asserted-by":"crossref","first-page":"10902","DOI":"10.1158\/0008-5472.CAN-06-2217","article-title":"Gonadotropin-releasing hormone promotes ovarian cancer cell invasiveness through c-Jun NH2-terminal kinase-mediated activation of matrix metalloproteinase (MMP)-2 and MMP-9","volume":"66","author":"Cheung","year":"2006","journal-title":"Cancer Res"},{"key":"2022060815534698600_bib33","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1158\/1078-0432.CCR-08-2525","article-title":"Estrous cycle modulates ovarian carcinoma growth","volume":"15","author":"Armaiz-Pena","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2022060815534698600_bib34","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1158\/1078-0432.CCR-07-0063","article-title":"The convergent development of molecular-targeted drugs for cancer treatment and prevention","volume":"13","author":"Lippman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022060815534698600_bib35","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-06-4490","article-title":"RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer","volume":"67","author":"Mabuchi","year":"2007","journal-title":"Cancer Res"},{"key":"2022060815534698600_bib36","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1475-2891-4-25","article-title":"Cactus pear: a natural product in cancer chemoprevention","volume":"4","author":"Zou","year":"2005","journal-title":"Nutr J"},{"key":"2022060815534698600_bib37","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ygyno.2007.07.077","article-title":"Antitumor activity of 4-(N-hydroxyphenyl)retinamide conjugated with poly(l-glutamic acid) against ovarian cancer xenografts","volume":"107","author":"Zou","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2022060815534698600_bib38","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1042\/BJ20070631","article-title":"Inhibition of calcium-independent phospholipase A2 suppresses proliferation and tumorigenicity of ovarian carcinoma cells","volume":"406","author":"Song","year":"2007","journal-title":"Biochem J"},{"key":"2022060815534698600_bib39","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.22854","article-title":"Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor \u03b3 ligand, on the growth of human ovarian cancers","volume":"110","author":"Xin","year":"2007","journal-title":"Cancer"},{"key":"2022060815534698600_bib40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1006\/gyno.2002.6663","article-title":"Effect of fenretinide on ovarian carcinoma occurrence","volume":"86","author":"De Palo","year":"2002","journal-title":"Gynecol Oncol"},{"key":"2022060815534698600_bib41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/89126","article-title":"In vivo molecular target assessment of matrix metalloproteinase inhibition","volume":"7","author":"Bremer","year":"2001","journal-title":"Nat Med"},{"key":"2022060815534698600_bib42","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1158\/1940-6207.CAPR-09-0064","article-title":"Early detection of oral neoplasia: watching with new eyes","volume":"2","author":"Kelloff","year":"2009","journal-title":"Cancer Prev Res"}],"container-title":["Cancer Prevention Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/2\/9\/792\/2336316\/792.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article-pdf\/2\/9\/792\/2336316\/792.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T12:45:20Z","timestamp":1654692320000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerpreventionresearch\/article\/2\/9\/792\/48610\/Effects-of-Oral-Contraceptives-or-a-Gonadotropin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9,1]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,9,10]]},"published-print":{"date-parts":[[2009,9,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1940-6207.capr-08-0236","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/1940-6207.22524981","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.6544515","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22524981.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22524984","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.22524984.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/1940-6207.c.6544515.v1","asserted-by":"object"}]},"ISSN":["1940-6207","1940-6215"],"issn-type":[{"value":"1940-6207","type":"print"},{"value":"1940-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,1]]}}}